Clinical Trial: Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07746180) titled 'Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis' on July 27.

Brief Summary: This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: ANCA-Associated Glomerulonephritis (AAGN) ANCA-Associated Vasculitis (AAV)

Intervention: DRUG: Obinutuzumab beta

Intravenous infusion of Obinutuzumab beta administered during the induction ...